SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs November 22 decision on Deramiocel for Duchenne muscular dystrophy, after management reaffirmed confidence in the therapy and said its application is in final review. Traders read the CEOs comments on labeling as potentially encouraging and speculate about short covering, while others stress that approval is uncertain given prior FDA concerns.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGRs steep, volatile selloff is driving a bearish debate, with traders blaming short pressure and insider or pre-IPO shareholder selling while bulls argue the companys growth in HELOC lending and tokenization remains intact. Upcoming earnings are a key focus, with some traders expecting strong operating results to counter concerns about valuation, share overhang, and management.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention after strong Q3 results and its first positive adjusted EBITDA, with traders pointing to Quake AI and the Northern Data GPU business as evidence its AI-infrastructure pivot is gaining traction. Bulls are touting short-squeeze potential, while skeptics question cash needs, ongoing GAAP losses, and the timing of the Georgia data-center expansion.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected Q3 results, raised outlook and large backlog have fueled a sharp rally and renewed interest in the AI infrastructure trade; the CEOs canceled stock-sale plan and comments on customer prepayments also eased some financing concerns. Traders are debating whether short covering can extend the rebound, while skeptics point to heavy debt, interest costs and potential dilution.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results showed strong revenue growth, improving margins and a raised outlook, but an earnings miss and negative adjusted EBITDA coincided with a sharp share-price decline. Traders are split between concerns about near-term profitability and claims of short- or options-driven selling, while many long-term holders view the pullback as an opportunity.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias generic-drug patent litigation remains unresolved after further deadline extensions, keeping traders focused on when a settlement or court progress might arrive. Frustration over managements limited communication and speculation about a buyout persist, while the latest earnings and raised guidance drew some positive reactions but have not eased concerns about the share price.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Traders are focused on MSCIs index review and the risk that Strategy could be excluded under rules affecting crypto-heavy companies, with some fearing forced selling while others argue the risk is already priced in or could trigger a reversal. Bitcoin weakness and concerns about share dilution add to the bearish debate.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Shares are drawing attention after Revolution Medicines reported a strong initial RASONQUE launch, but the stock fell despite the upbeat results. Traders are debating whether the launch can sustain its momentum amid high spending and valuation concerns, while some view the pullback as an overreaction.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Unconfirmed takeover and M&A chatterincluding claims of European investor interestis drawing attention to Clorox, with some traders citing elevated volume and a sharp recent run while others are taking profits or cautioning that the rumor is unverified.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake is drawing attention around its FDA application for sonelokimab in hidradenitis suppurativa, with traders focused on the pending decision on whether the BLA will be accepted and what review timeline it may receive. Bulls point to the drugs clinical results and competitive positioning, while skeptics stress regulatory uncertainty and the costs and dilution risks of launching independently.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
